We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

147 hedge funds and large institutions have $400M invested in Intercept Pharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 36 increasing their positions, 47 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

21% more capital invested

Capital invested by funds: $331M → $400M (+$69M)

6% more funds holding

Funds holding: 139147 (+8)

10% less call options, than puts

Call options by funds: $25.3M | Put options by funds: $28M

23% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 47

Holders
147
Holders Change
+8
Holders Change %
+5.76%
% of All Funds
2.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
33
Increased
36
Reduced
47
Closed
25
Calls
$25.3M
Puts
$28M
Net Calls
-$2.67M
Net Calls Change
+$3.57M
Name Holding Trade Value Shares
Change
Change in
Stake
State Street
1
State Street
Massachusetts
$53M +$1.83M +108,825 +3%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$40.4M -$1.48M -87,608 -3%
BlackRock
3
BlackRock
New York
$36.4M -$2.21M -131,371 -6%
Vanguard Group
4
Vanguard Group
Pennsylvania
$32.1M -$14.5M -858,504 -30%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$20.1M +$20.8M +1,233,000 New
SB
6
Samsara BioCapital
California
$10.4M
Macquarie Group
7
Macquarie Group
Australia
$10.1M -$66K -3,915 -0.6%
Jacobs Levy Equity Management
8
Jacobs Levy Equity Management
New Jersey
$9.59M +$923K +54,746 +10%
Millennium Management
9
Millennium Management
New York
$9.12M +$9.43M +559,678 New
Two Sigma Advisers
10
Two Sigma Advisers
New York
$8.95M +$1.63M +96,700 +21%
Two Sigma Investments
11
Two Sigma Investments
New York
$8.8M +$1.5M +88,733 +20%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$8.38M -$3.11M -184,500 -26%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$7.86M -$251K -14,896 -3%
EAM
14
EULAV Asset Management
Florida
$7.33M -$3.54M -210,000 -32%
Goldman Sachs
15
Goldman Sachs
New York
$7.07M +$2.28M +135,475 +45%
Rockefeller Capital Management
16
Rockefeller Capital Management
New York
$6.33M +$863K +51,209 +15%
Bank of America
17
Bank of America
North Carolina
$6.17M +$2.87M +170,116 +81%
Citigroup
18
Citigroup
New York
$5.45M +$1.95M +115,538 +53%
EAM
19
Eventide Asset Management
Massachusetts
$5.33M +$5.52M +327,444 New
Northern Trust
20
Northern Trust
Illinois
$4.53M -$119K -7,057 -2%
Rafferty Asset Management
21
Rafferty Asset Management
New York
$4.23M +$1.89M +112,239 +76%
Renaissance Technologies
22
Renaissance Technologies
New York
$3.97M +$741K +43,969 +22%
Voloridge Investment Management
23
Voloridge Investment Management
Florida
$3.84M -$777K -46,066 -16%
Morgan Stanley
24
Morgan Stanley
New York
$3.16M +$359K +21,289 +12%
JP Morgan Chase
25
JP Morgan Chase
New York
$2.99M -$250K -14,826 -7%

ICPT Hedge Fund Activity: Q4 2021 in Review

147 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2021, worth a combined $400M — up 21% from $331M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ICPT positions and 25 closed out — a net gain of 8 holders — while 36 added to existing stakes and 47 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $20.8M. The largest seller was Vanguard Group, cutting an estimated $14.5M.

  • 147 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2021, up from 139 in Q3 2021.
  • Funds reported $400M of Intercept Pharmaceuticals, Inc. stock for Q4 2021, up 21% quarter-over-quarter.
  • 33 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2021 and 25 closed out, a net change of +8 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2021 was Adage Capital Partners, an estimated $20.8M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q4 2021 was Vanguard Group, an estimated $14.5M sold.

Based on aggregated 13F filings for Q4 2021.